January 1, 2022 is a special day for Zhang Wei (pseudonym). Because the new version of the national medical insurance drug catalogue was officially implemented, the price of a variety of drugs was significantly reduced, and Zhang Wei received usonumab treatment for the first time after the price reduction, becoming the first patient with inflammatory bowel disease (IBD) in Hubei Province to enjoy the price reduction of uszunomab. Abdominal pain, diarrhea and fistula that have plagued Zhang Wei for many years improved after medication, and the quality of life improved. Zhang Wei saw the hope of a happy life again.
Significant price reductions to reduce the economic burden on patients with IBD
In recent years, the incidence of IBD in mainland China has increased year by year, and it has gradually become the main intestinal disease of young and middle-aged people in mainland China. Zhang Wei from Yichang, Hubei Province, was suspected of diagnosing Crohn's disease (CD) in 2011, and was diagnosed with biological agents in 2015, which was originally very effective and had reached endoscopic healing, but due to economic pressure, Zhang Wei had to stop the drug. This stop, the time is 2020. After the disease progressed, the application of biological agents failed again, and Zhang Wei had to go to the IBD center of the provincial city university for treatment.
In 2021, Zhang Wei came to the Zhongnan Hospital of Wuhan University, and Director Ye Mei of the Department of Gastroenterology made an individualized diagnosis and treatment plan according to the characteristics of the patient's long medical history, wide range of lesions, severe endoscopic lesions, combined fistula, and the use of two biological agents, and recommended that patients use usenuzumab. It coincided with the entry of usonumab into the "2021 Edition of the National Medical Insurance Drug Catalog". On the first day of 2022, Zhang Wei used using ussnuzumab after the price reduction, which greatly reduced the economic burden.
It is reported that after the inclusion of the new drug list in the medical insurance negotiations, the price of the intravenous infusion dosage form of usonumab 130 mg is 2531.24 yuan / bottle, and the price of 90 mg subcutaneous injection dosage form is 7340.6 yuan / stick.
Professional team to create a multidisciplinary diagnosis and treatment model for IBD
The IBD Diagnosis and Treatment Center of Zhongnan Hospital of Wuhan University, where Director Ye Mei is located, is one of the earliest centers in China to establish and carry out IBD sub-specialties, and is well-known in IBD diagnosis and treatment. In 2017, the first "Biologics Infusion Center" in Hubei Province was settled in the center, which optimized the appointment mechanism while standardizing the biological preparation infusion standards and guiding the management of chronic diseases, improving the patient experience and improving patient compliance.
The IBD-MDT team of Zhongnan Hospital has been established for more than ten years, and the core members include gastroenterology, colorectal and surgery, imaging center, pathology center, and the expanded members include pediatrics, psychiatry, rheumatology and immunology, nutrition, obstetrics and gynecology, etc. The IBD team conducts MDT discussions every two weeks. The multidisciplinary approach helps patients make a definitive diagnosis as quickly as possible and facilitates disease assessment, patient stratification management, and surgical timing, as well as timely and standardized treatment.
The IBD Diagnosis and Treatment Center of Zhongnan Hospital attracts many patients with its rich diagnosis and treatment experience, harmonious doctor-patient relationship and good chronic disease management mode. In order to help patients better understand IBD, at the same time as the diagnosis and treatment work, the IBD diagnosis and treatment team carries out monthly patient education activities, conducts systematic science popularization, and answers questions at any time through QQ groups, WeChat groups, etc., so that the majority of IBD patients benefit.
Patient education activities
Diagnosis and treatment training to help early diagnosis and standardized treatment
IBD is not uncommon today, but some doctors still don't know enough about IBD. The cause of IBD is unknown, the diagnosis is difficult, and misdiagnosis, missed diagnosis, and delayed diagnosis occur from time to time. Therefore, patients with IBD face the problem of difficult and long diagnosis time. Some patients have missed the best time for treatment when they are diagnosed, resulting in unsatisfactory treatment results. The long diagnosis and treatment process has also deeply damaged the patient's confidence in treatment and greatly increased the patient's economic burden.
In order to help more doctors understand IBD and improve IBD diagnosis and treatment capabilities, in 2016, Zhongnan Hospital of Wuhan University took the lead in establishing an "IBD Collaboration Group" in Hubei Province, including 34 third-class hospitals and 31 second-class hospitals. Through on-site teaching and online training, the IBD diagnosis and treatment team regularly conducts special training on IBD diagnosis and treatment for municipal hospitals and county-level hospitals in Hubei Province, improves the diagnosis and treatment capabilities of local hospitals, drives the continuous improvement of the diagnosis and treatment level of intestinal diseases, and trains specialist doctors and specialist nurses, and establishes a two-way referral and consultation mechanism to benefit the majority of patients.
Wei Zhang is a member of the IBD patient population. It is estimated that by 2025, the number of IBD patients in China will reach 1.5 million. Behind the numbers are faces that long to live like normal people. "Every small group should not be abandoned", may every IBD patient get effective treatment and live happily!
end